Why GC Biopharma’s ALYGLO research push could matter more than another conference poster
IVIG differentiation is getting technical. GC Biopharma’s ALYGLO push shows why molecular trust may shape the next adoption battle.
Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.